Drugs in Dev. Nephrology
Phase II
China 
Lead Product(s) : SHR-2173
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SHR-2173 is a large molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Lupus Nephritis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 17, 2025
Lead Product(s) : SHR-2173
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Efgitasialase Alfa
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
HLX79 + Rituximab vs Placebo Safety & Efficacy In Active Glomerulonephritis
Details : HLX79 (Efgitasialase Alfa) is a Protein drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Glomerulonephritis, Membranous.
Product Name : HLX79
Product Type : Protein
Upfront Cash : Inapplicable
June 26, 2025
Lead Product(s) : Efgitasialase Alfa
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SC0062
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
BioCity’s SC0062 Meets Phase 2 Primary Endpoint in Diabetic Kidney Disease
Details : SC0062 is one of the most unique, oral endothelin A (ETA)-receptor selective antagonist, small molecule drug. It is being evaluated for the treatment of diabetic kidney disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 25, 2025
Lead Product(s) : SC0062
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CM313
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of CM313 in Subject With IgA Nephropathy
Details : CM313 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glomerulonephritis, IGA.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 17, 2025
Lead Product(s) : CM313
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AP306
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AP306 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hyperphosphatemia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : AP306
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MY008211A
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MY008211A is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glomerulonephritis, IGA.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 13, 2024
Lead Product(s) : MY008211A
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : JMKX003142
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Dose-finding Study of JMKX003142 in Treatment of Renal Edema
Details : JMKX003142 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Edema.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 01, 2024
Lead Product(s) : JMKX003142
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HSK39297
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN
Details : HSK39297 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glomerulonephritis, IGA.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 01, 2024
Lead Product(s) : HSK39297
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : JMKX003002
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JMKX003002 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hyperphosphatemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 29, 2024
Lead Product(s) : JMKX003002
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zuberitamab
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy
Details : Zuberitamab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Primary Membranous Nephropathy.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
October 15, 2024
Lead Product(s) : Zuberitamab
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
